<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60518">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02069535</url>
  </required_header>
  <id_info>
    <org_study_id>AV-X-03</org_study_id>
    <secondary_id>2013-004720-11</secondary_id>
    <nct_id>NCT02069535</nct_id>
  </id_info>
  <brief_title>An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy</brief_title>
  <official_title>An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is an open, national, multi-centre trial. The main objective of this trial is  to
      assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica by measurement
      of related Adverse Events.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency of patients with IMP-related AEs</measure>
    <time_frame>6 treatment weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients with systemic reactions</measure>
    <time_frame>6 weeks of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>AVANZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVANZ Cupressus</intervention_name>
    <arm_group_label>AVANZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A documented clinically relevant history of Cupressus arizonica pollen induced
             allergic rhinoconjunctivitis with or without asthma for at least one year prior to
             trial entry.

          -  Positive Skin Prick Test (SPT) response to Cupressus arizonica pollen (wheal diameter
             ≥ 3 mm)

        Exclusion Criteria:

          -  History of severe asthma exacerbation or emergency room visit or admission for asthma
             in the previous 12 months.

          -  Previous treatment with immunotherapy with Cupressus arizonica pollen extract within
             the last 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment
             has been discontinued before reaching maintenance dose; for SLIT 3 months in the last
             5 years is accepted).

          -  Ongoing treatment with any allergen-specific immunotherapy product.

          -  A history of anaphylaxis with cardiorespiratory symptoms (immunotherapy,
             exercise-induced, food allergy, drugs or an idiopathic reaction).

          -  A systemic disease affecting the immune system (e.g. insulin-dependent diabetes,
             autoimmune disease, immune complex disease, or immune deficiency disease whether
             acquired or not).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Montserrat Fernández Rivas, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico Universitario San Carlos - Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Santiago Martín, MsC</last_name>
    <phone>+34913276127</phone>
    <email>smaes@alk.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pilar Rico, PhD</last_name>
    <phone>+34913276127</phone>
    <email>prnes@alk.net</email>
  </overall_contact_backup>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cupressus arizonica</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
